Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Evaluation of Gemcitabine (Gemzar®, LY188011) in the Treatment of Recurrent or Persistent Endometrial Carcinoma

NCT00820898 is registered in ClinicalTrials.gov with Gynecologic Oncology Group as lead sponsor.

NCT NCT00820898
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00820898 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Evaluation of Gemcitabine (Gemzar®, LY188011) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Lead sponsor
Gynecologic Oncology Group
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2009
Completion date
Not reported
Enrollment
24 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial adenocarcinoma, endometrial adenosquamous carcinoma, endometrial clear cell adenocarcinoma, recurrent uterine corpus carcinoma